Clinical trials
Targeted Therapy clinical trials
Below are recruiting targeted therapy clinical trials, each written for real people, not researchers. We’re tracking 292 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06364176RecruitingPhase 2
Adding losartan to improve Trikafta response in CF
This study tests whether adding the blood pressure medication losartan can help the standard CF drug Trikafta work better by reducing inflammation. It's for people with CF who still have high sweat chloride levels despite taking Trikafta.
Kansas City, KansasAges 12 years+ - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT03311503RecruitingPhase 1/Phase 2
Gene therapy for X-linked SCID in young children
This trial tests a gene therapy using a lentivirus to give missing immune system instructions in children with X-linked SCID (SCID-X1). It also uses a low dose of targeted chemotherapy (busulfan) to help the new genes work, and it requires long-term follow-up for safety.
Los Angeles, CaliforniaAges birth–5 years - NCT05096273Recruiting
Training for control and expectations in PNES therapy
This study tests a treatment approach that aims to improve a sense of control and change symptom expectations for children or teens with psychogenic non-epileptic seizures (PNES). It also involves family support so the treatment fits your home life and goals.
Birmingham, AlabamaAges 11–18 - NCT03109288RecruitingPhase 1/Phase 2
Biomarker-guided combination treatment for residual multiple sclerosis activity
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
Bethesda, MarylandAges 18–120 - NCT04794777RecruitingPhase 3
Tests targeted scans and rescue radiation for returning prostate cancer
This trial studies whether a targeted scan (PSMA PET/CT) can help doctors choose the best “salvage” radiation treatment when prostate cancer comes back by PSA blood tests after surgery. It may help some people avoid under- or over-treating the areas where the cancer is returning.
Gothenburg, GöteborgAges 18 years+ - NCT05136703Recruiting
Study depression treatment effects in people living with HIV
This study looks at how depression and its treatment may affect the brain and immune-related body systems in people with HIV. You may be eligible if you have depression and a well-controlled HIV viral load, and you can safely complete brain MRI scans.
Coral Gables, FloridaAges 18 years+ - NCT05577091RecruitingPhase 1
CAR-T cell therapy for recurrent glioblastoma
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
Beijing, Beijing MunicipalityAges 18–70 - NCT06785519RecruitingEarly Phase 1
CAR-T cell therapy for stubborn lupus kidney disease
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07202351Recruiting
Sleep support for quitting smoking or cannabis
This trial tests whether adding sleep-focused help to standard quit-smoking or quit-cannabis therapy improves your chances of success. It is for people who are not already being treated for sleep problems.
Paris, Île-de-France RegionAges 18 years+ - NCT05674825RecruitingPhase 1/Phase 2
Personalized treatment using tumor test results for aggressive cancers
This early-phase study tests whether a personalized cancer treatment plan based on your tumor’s test results can help people with aggressive cancers that are hard to treat. It may be an option if standard treatments didn’t work, aren’t possible for you, or you have few treatment choices.
Milwaukee, WisconsinAges 18 years+ - NCT07168213Recruiting
Comparing oxygen monitors during high-flow nasal oxygen
This study tests whether two different oxygen monitors change how much extra oxygen doctors give you during high-flow nasal oxygen therapy. If you are in the ICU and already on this type of oxygen, the researchers want to see if using a different monitor helps keep your oxygen levels stable.
Québec, QuebecAges 18 years+ - NCT06279923RecruitingEarly Phase 1
CAR-T cells for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06662006RecruitingPhase 2
Nal-IRI chemo with immunotherapy and radiation for pancreatic cancer
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Nanjing, JiangsuAges 18–75 - NCT07648264RecruitingPhase 3
Immune Boost Treatment After CAR-T or TCE Therapy
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
Orange, CaliforniaAges 18 years+ - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT07432334RecruitingPhase 1
CAR T-cell therapy for hard-to-treat lupus
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
HanoiAges 16–55 - NCT07498933Recruiting
FAP-targeted imaging for lung cancer
This trial uses a special imaging test (PET/NIR) to find lung cancer cells. It may help doctors see tumors more clearly before and after treatment.
Beijing, Beijing MunicipalityAges 18–70 - NCT05814822Recruiting
CBT for sleep problems in adults using cannabis
This study looks at a sleep-focused treatment to help adults who have ongoing insomnia and also use cannabis regularly. If sleep improves, the trial hopes it may also improve overall outcomes for cannabis use.
Ann Arbor, MichiganAges 21 years+ - NCT05440214Recruiting
Therapy to reduce suicide risk in people with psychosis
This trial tests an approach aimed at emotional ups-and-downs to help lower suicide risk in people who have psychosis and are at higher risk for suicidal thoughts or behaviors. If you qualify, you would get outpatient mental health care while participating in the study.
Baltimore, MarylandAges 18 years+ - NCT06231966Recruiting
High-dose statin combo vs. standard statin for artery disease
This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.
SeoulAges 19–80 - NCT06473259Recruiting
Comparing treatments for hormone-sensitive metastatic prostate cancer
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Orbassano, TorinoAges Any age - NCT07673172Enrolling by invitation
Heart Health Program for Teens and Young Adults with Autism
This trial tests a two-part program to improve heart health in people with autism who are above a healthy weight. It may help you learn ways to take better care of your heart.
Los Angeles, CaliforniaAges 9–26 - NCT06676007Recruiting
Early use of a targeted budesonide for IgA nephropathy
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Chengdu, SichuanAges 18–75
Hear when a new Targeted Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for targeted therapy?
- Yes. Clin2 currently lists 292 recruiting targeted therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a targeted therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a targeted therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.